Consistent with the findings of the basket TROPiCS-03 study, SG appears to be a promising novel therapy option for R/M HNSCC after failure of immunotherapy and chemotherapy, particularly in patients with Trop-2 overexpression. This evidence concerns the gene TACSTD2 and head and neck squamous cell carcinoma.